Ftse Mib
33.746,66
-1,60%
DAX
17.932,17
-1,10%
S&P 500
5.035,69
-1,57%
NASDAQ Composite
15.657,82
-2,04%
Bitcoin
57.051,41
-5,86%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. AMEX AIM ImmunoTech Inc (AIM) AIM ImmunoTech Inc (AIM) Notizie

AIM ImmunoTech Inc

AIM
0,4085
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 10:00:00
Dati in Delay di 15 minuti
Borsa: AMEX
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
29/4/202414:55GLOBEAIM ImmunoTech Announces First Dose Level is Generally..
25/4/202414:45GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
18/4/202414:45GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
15/4/202414:55GLOBEAIM ImmunoTech Announces Charles Lapp, MD, as a Consulting..
11/4/202417:00GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
10/4/202414:21GLOBEAIM ImmunoTech Announces Positive Top-Line, Protocol-Planned..
02/4/202413:30GLOBEAIM ImmunoTech Reports Fourth Quarter and Full Year 2023..
28/3/202413:05GLOBEAIM ImmunoTech to Present at the MedInvest Biotech & Pharma..
26/3/202414:05GLOBEAIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023..
25/3/202414:05GLOBEAIM ImmunoTech Announces Publication of Positive Findings..
22/3/202413:55GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
20/3/202414:25GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
15/3/202413:45GLOBEAIM ImmunoTech to Participate in the Virtual Investor Lunch..
07/3/202414:45GLOBEAIM ImmunoTech Announces Launch of CEO Corner Platform
29/2/202414:45GLOBEAIM ImmunoTech Outlines Recent Progress Across Clinical..
21/2/202416:37EDGAR2Form D/A - Notice of Exempt Offering of Securities: [Amend]
20/2/202422:31EDGAR2Form 8-K - Current report
14/2/202414:55GLOBEAIM ImmunoTech Announces First Subject Dosed in the..
09/2/202421:47EDGAR2Form 8-K - Current report
08/2/202414:50GLOBEAIM ImmunoTech Reports Positive Topline Results from Phase 2..
25/1/202423:00EDGAR2Form 8-K - Current report
24/1/202415:10GLOBEAIM ImmunoTech Receives Erasmus Medical Center Ethics Board..
22/1/202414:55GLOBEAIM ImmunoTech Announces that the First Subject is Enrolled..
10/1/202419:42EDGAR2Form 8-K - Current report
10/1/202414:45EDGAR2Form 8-K - Current report
10/1/202414:45GLOBEAIM ImmunoTech Announces Open Enrollment for Phase 1b/2..
05/1/202419:32BWAIM Shareholders Elect All Four Company Director Nominees at..
03/1/202422:24EDGAR2Form SC 13D/A - General statement of acquisition of..
03/1/202422:24EDGAR2Form DFAN14A - Additional definitive proxy soliciting..
03/1/202422:05PRNUSKellner Seeking Expedited Appeal of Delaware Court Finding..
29/12/202314:15EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
29/12/202314:00BWDelaware Court Rules in Favor of AIM ImmunoTech and Upholds..
28/11/202322:54EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
28/11/202322:30BWAIM ImmunoTech Provides Update Regarding Annual Meeting
27/11/202318:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/11/202315:05GLOBEAIM ImmunoTech Bolsters Intellectual Property Estate for..
21/11/202318:00GLOBEAIM ImmunoTech Completes Treatment of Last Subject in Phase..
20/11/202323:29EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
20/11/202315:05EDGAR2Form DFAN14A - Additional definitive proxy soliciting..
20/11/202313:30EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
16/11/202315:21EDGAR2Form DFAN14A - Additional definitive proxy soliciting..
15/11/202313:30EDGAR2Form 8-K - Current report
15/11/202313:30GLOBEAIM ImmunoTech Reports Third Quarter 2023 Financial Results..
14/11/202316:00GLOBEAIM ImmunoTech Announces Publication of Data from Roswell..
09/11/202314:05GLOBEAIM ImmunoTech to Discuss Third Quarter 2023 Financial..
08/11/202322:15EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
08/11/202314:45EDGAR2Form 8-K - Current report
08/11/202314:45GLOBEAIM ImmunoTech Announces Encouraging Translational Data from..
07/11/202312:03EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
06/11/202315:25BWAIM ImmunoTech Files Definitive Proxy Statement and Sends..
Apertura: Min: Max:
Chiusura: 0,4085

La tua Cronologia

AMEX
AIM
AIM ImmunoTech
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network